Business Wire

CA-GLOBALLOGIC

7.12.2021 14:02:19 CET | Business Wire | Press release

Share
GlobalLogic OTT Service Offerings for Streaming Platforms Proven to Significantly Reduce Go-to-Market Timelines

GlobalLogic Inc. , a Hitachi Group Company and leader in Digital Engineering, today announced availability of technology accelerators that significantly reduce time to market of custom Over-The-Top (OTT) applications by as much as 30 to 50 percent. This is accomplished through the development of advanced solution accelerators for application development and testing across all major mainstream OTT platforms. GlobalLogic delivers this capability through a software engineering team with deep expertise in the end-to-end OTT value chain, which has developed more than 200 complex applications over the past ten years as part of multiple global OTT services rollouts.

OTT Digital Accelerators

The world of streaming applications has become immense and complex. Consumers demand high-quality, immersive viewing experiences from any provider on any device. To satisfy this demand and increase consumer engagement, OTT service providers must develop extremely efficient, native application experiences across multiple platforms, including living room (Smart TV, Streaming Device), mobile, web and gaming environments. Streaming applications must be highly reliable and resilient, to assure content will be available 24/7. And systems must be robust to enable providers to monetize the service. Global rollouts add additional complexity to the entire development process.

Over the last ten years, GlobalLogic has been delivering custom OTT platform application development services for more than 20 streaming platform customers—resulting in the creation of best practice frameworks and accelerators for faster development of OTT services. The GlobalLogic OTT Channel Development Accelerator and TestLab are two such accelerators enabling GlobalLogic customers such as media companies to create exceptionally reliable, immersive experiences for consumers.

The accelerators are platform-agnostic—compatible with the most commonly used consumer streaming services—as well as device-agnostic, supporting gaming consoles, set-top boxes, smartphones, PCs, and tablets. They also support management of multiple devices from a single interface.

OTT Channel Development Accelerator : A customizable media platform that enables the creation of a fully functional, completely branded OTT channel or app from idea to launch-ready in just 2.5 months.1

Key Features and Benefits:

  • Common code base for native applications on similar platforms
  • Support for all VOD models (AVOD, SVOD, TVOD)
  • Advanced, customizable UI/UX features such as unlimited screens or background video
  • Versatile monetization options such as in-app purchases, subscription billing, or ad-based services
  • Code base owned by client with flexible GlobalLogic engagement models

OTT TestLab Accelerator : A unified infrastructure that schedules automated quality assurance tests on all OTT devices. Clients can test on their own devices, or leverage GlobalLogic’s devices and labs. This is further enhanced by custom, automated test cases for all major platforms and use cases.

Key Features and Benefits:

  • Makes testing possible as soon as channel development project begins
  • Jump starts continuous integration/continuous delivery (CI/CD) pipelines
  • Simple KPI set up and viewing with easy app adjustment capabilities based on results
  • Eliminates need to purchase duplicate equipment dedicated to each device
  • 3,000+ test devices spanning all major platforms, vendors, use-cases

“The OTT application landscape has grown dramatically larger and more complex over the past few years, and our clients are seeking partners to help navigate it,” said Arun Mukunda, VP and Global Head, Media and Entertainment, GlobalLogic. “Having delivered hundreds of complex OTT applications, GlobalLogic is in a unique position to help our clients rapidly create and launch high quality streaming services on a global scale at a pace never before possible.”

About GlobalLogic

GlobalLogic (www.globallogic.com ) is a leader in digital engineering. We help brands across the globe design and build innovative products, platforms, and digital experiences for the modern world. By integrating experience design, complex engineering, and data expertise – we help our clients imagine what’s possible and accelerate their transition into tomorrow’s digital businesses. Headquartered in Silicon Valley, GlobalLogic operates design studios and engineering centers around the world, extending our deep expertise to customers in the automotive, communications, financial services, healthcare and life sciences, manufacturing, media and entertainment, semiconductor, and technology industries. GlobalLogic is a Hitachi Group Company operating under Hitachi, Ltd. (TSE: 6501), which contributes to a sustainable society with a higher quality of life by driving innovation through data and technology as the Social Innovation Business.

GlobalLogic is a trademark of GlobalLogic. All other brands, products or service names are or may be trademarks or service marks of their respective owners.


1 Approximate time frame based on building and launching a standard app. More complex apps may take longer.

Link:

ClickThru

Social Media:

https://www.facebook.com/GlobalLogic/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release

A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us

Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release

Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas

ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release

OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future

Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release

Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority

Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release

Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye